Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data., PMID:40294847
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials., PMID:40037388
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study., PMID:39465531
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)., PMID:39209068
Real-world biologics response and super-response in the International Severe Asthma Registry cohort., PMID:38923444
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma., PMID:38711495
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma., PMID:38329781
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma., PMID:38272375
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study., PMID:38163585
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study., PMID:37956679
Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma., PMID:37659435
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma., PMID:37059696
Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both., PMID:36929509
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization., PMID:36915284
Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study., PMID:36740960
Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry., PMID:36201124
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study., PMID:36066123
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype., PMID:36028446
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials., PMID:35775319
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose., PMID:35398549
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial., PMID:35217003
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count., PMID:35007624
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma., PMID:34990866
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma., PMID:34879449
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma., PMID:34706171
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study., PMID:34619104
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study., PMID:34597534
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials., PMID:34459002
Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma., PMID:34266940
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma., PMID:33465455
[Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina]., PMID:32558511
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis., PMID:32474156
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials., PMID:32066536
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial., PMID:31579676
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials., PMID:31543428
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis., PMID:31351189
The expression of brown fat-associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis., PMID:30737786
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma., PMID:30359681
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma., PMID:29782224
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma., PMID:29782217
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma., PMID:29725983
Honokiol exerts dual effects on browning and apoptosis of adipocytes., PMID:29136581
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects., PMID:28683596
Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo., PMID:27640183
Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model., PMID:27467592
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial., PMID:27130691
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study., PMID:27056586
Human 'brite/beige' adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice., PMID:26808348
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials., PMID:25736990
Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel., PMID:25268703
For research use only. Not for human or drug use.
